Moderna’s Phase 1 vaccine trial produces antibodies against SARS-CoV-2
Category: #health  By Mateen Dalal  Date: 2020-05-19
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Moderna’s Phase 1 vaccine trial produces antibodies against SARS-CoV-2

Moderna, Inc., an American biotechnology company, recently announced that its coronavirus vaccine candidate has produced protective antibodies among a group of healthy volunteers.

Early data has been collected from the trial of the company’s experimental vaccine candidate, which is the 1st to be tested in the U.S. The data comes from the 45-subject safety trial that was started in March. Its vaccine candidate is among several candidates that are under development for use against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the coronavirus strain that causes COVID-19 disease. According to the overall data collected from the study, it showed the safety of the vaccine as participants generated antibodies against this virus.

According to Dr. Amesh Adalja, JHCHS’s (John Hopkins Center for Health Security) infectious disease expert, the significant findings of this Phase 1 clinical trial have been generated from 8 people who took part in the trial that was designed to examine the vaccine’s safety, and not the efficacy.

In this Phase 1 trial, researchers examined the blood samples of the subjects to identify whether the vaccine generates antibodies that can fight off the infection theoretically. This early data from the trial offers tentative hopes of a positive result of the vaccine among those that are in the advanced development stage. This result is believed to significantly aid the global efforts in combating the pandemic.

The development of a vaccine is considered as an important step towards lifting various precautionary measures imposed by the government, including social distancing guidelines. It could also result in a safe reopening of schools, events, and economies across the globe. The novel coronavirus has infected nearly 4.7 million globally and claimed the lives of around 300,000 people. This has spurred a global race among governments, academic institutions, and drug makers to develop a vaccine.

Source credits:https://www.hindustantimes.com/world-news/vaccine-developers-report-first-positive-sign-in-human-trial/story-FsuAwE2dscboq65orUBZcL.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

By Mateen Dalal

The parent company of German airline Deutsche Lufthansa AG, Lufthansa Group, reportedly said it would purchase a total of 10 long-haul aircraft, including 5 Boeing B787-9s and 5 Airbus A350-900s, to replace aging Airbus A340 planes in an effort to mo...

Facebook, Google sign content deals with Australia’s Seven West Media

Facebook, Google sign content deals with Australia’s Seven West Media

By Mateen Dalal

Seven West Media, an Australian newspaper and television firm, has reportedly signed a content deal with Facebook Inc. and Google LLC in the wake of recent landmark laws that have enabled the industry to obtain new revenue sources and adapt to the in...

Microsoft considered reducing Xbox Store fee to revive console gaming

Microsoft considered reducing Xbox Store fee to revive console gaming

By Mateen Dalal

Multinational tech-giant Microsoft was reportedly looking to lower its Xbox store commission fee to a meager 12% from the previous 30%, as per confidential documents submitted in the Epic Games and Apple case. The document from January also contains...